메뉴 건너뛰기
Virulence
Volumn 5, Issue 1, 2014, Pages 143-153
Animal models of sepsis
Author keywords

Drotrecogin alfa (activated); Endotoxin; Lipopolysaccharide; Platelet activating factor; Tifacogin; Tumor necrosis factor
Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 3 BROMO 5 [N PHENYL N [2 [[2 (1, 2, 3, 4 TETRAHYDRO 2 ISOQUINOLYLCARBONYLOXY) ETHYL] CARBAMOYL] ETHYL] CARBAMOYL] 1 PROPYLPYRIDINIUM NITRATE; 3 BROMO 5 [N PHENYL N [2 [[2 (1,2,3,4 TETRAHYDRO 2 ISOQUINOLYLCARBONYLOXY)ETHYL]CARBAMOYL]ETHYL]CARBAMOYL] 1 PROPYLPYRIDINIUM NITRATE; AFELIMOMAB; ANTIINFECTIVE AGENT; ANTITHROMBIN III; CB0006; CENTOXIN; CYTOFAB; DELTIBANT; DROTRECOGIN; ERITORAN; ETANERCEPT; GINKGOLIDE B; GR 270773; HYDROCORTISONE; IBUPROFEN; LENERCEPT; LEXIPAFANT; MAB T88; METHYLPREDNISOLONE; MINERALOCORTICOID; N(G) METHYLARGININE; PAFASE; RBP121; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT THROMBOMODULIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RESATORVID; TALACTOFERRIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;
EID: 84890861186     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.26083     Document Type: Review
Times cited : (314)
References (123)
  • 1
    • 0025354406 scopus 로고
    • Laboratory models of sepsis and septic shock
    • PMID:2199735
    • Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res 1990; 49:186-96 PMID:2199735. http://dx.doi.org/10.1016/0022-4804(90)90260-9.
    • (1990) J Surg Res , vol.49 , pp. 186-196
    • Fink, M.P.1    Heard, S.O.2
  • 2
    • 0019906260 scopus 로고
    • Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli
    • PMID:6752708
    • Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307:1225-30 PMID:6752708. http://dx.doi.org/10.1056/NEJM198211113072001.
    • (1982) N Engl J Med , vol.307 , pp. 1225-1230
    • Ziegler, E.J.1    McCutchan, J.A.2    Fierer, J.3    Glauser, M.P.4    Sadoff, J.C.5    Douglas, H.6    Braude, A.I.7
  • 3
    • 0026552353 scopus 로고
    • Anti-endotoxin monoclonal antibodies
    • PMID:1552919
    • Warren HS, Danner RL, Munford RS. Anti-endotoxin monoclonal antibodies. N Engl J Med 1992; 326:1153-7 PMID:1552919. http://dx.doi.org/10.1056/NEJM199204233261711.
    • (1992) N Engl J Med , vol.326 , pp. 1153-1157
    • Warren, H.S.1    Danner, R.L.2    Munford, R.S.3
  • 5
    • 0028557981 scopus 로고
    • Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebocontrolled trial
    • CHESS Trial Study Group, PMID:8198341
    • McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR; CHESS Trial Study Group. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebocontrolled trial. Ann Intern Med 1994; 121:1-5 PMID:8198341. http://dx.doi.org/10.7326/0003-4819-121-1-199407010-00001.
    • (1994) Ann Intern Med , vol.121 , pp. 1-5
    • McCloskey, R.V.1    Straube, R.C.2    Sanders, C.3    Smith, S.M.4    Smith, C.R.5
  • 6
    • 0028018567 scopus 로고
    • Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebo-controlled multicenter trial
    • IL-1RA Sepsis Syndrome Study Group. PMID:8124953
    • Fisher CJ Jr., Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA; IL-1RA Sepsis Syndrome Study Group. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22:12-21 PMID:8124953.
    • (1994) Crit Care Med , vol.22 , pp. 12-21
    • Fisher Jr., C.J.1    Slotman, G.J.2    Opal, S.M.3    Pribble, J.P.4    Bone, R.C.5    Emmanuel, G.6    Ng, D.7    Bloedow, D.C.8    Catalano, M.A.9
  • 7
    • 0028239555 scopus 로고
    • Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial
    • Phase III rhIL-1ra Sepsis Syndrome Study Group, PMID:8196140
    • Fisher CJ Jr., Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271:1836-43 PMID:8196140. http://dx.doi.org/10.1001/jama.1994.03510470040032.
    • (1994) JAMA , vol.271 , pp. 1836-1843
    • Fisher Jr., C.J.1    Dhainaut, J.F.2    Opal, S.M.3    Pribble, J.P.4    Balk, R.A.5    Slotman, G.J.6    Iberti, T.J.7    Rackow, E.C.8    Shapiro, M.J.9    Greenman, R.L.10
  • 8
    • 0030877935 scopus 로고    scopus 로고
    • Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial
    • The Interleukin-1 Receptor Antagonist Sepsis Investigator Group, PMID:9233735
    • Opal SM, Fisher CJ Jr., Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25:1115-24 PMID:9233735. http://dx.doi.org/10.1097/00003246-199707000-00010.
    • (1997) Crit Care Med , vol.25 , pp. 1115-1124
    • Opal, S.M.1    Fisher Jr., C.J.2    Dhainaut, J.F.3    Vincent, J.L.4    Brase, R.5    Lowry, S.F.6    Sadoff, J.C.7    Slotman, G.J.8    Levy, H.9    Balk, R.A.10
  • 9
    • 8544262221 scopus 로고    scopus 로고
    • Monoclonal Anti-TNF: A Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels
    • PMID:15640628
    • Panacek EA, Marshall JC, Albertson TE, Johnson DH, Johnson S, MacArthur RD, Miller M, Barchuk WT, Fischkoff S, Kaul M, et al.; Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32:2173-82 PMID:15640628.
    • (2004) Crit Care Med , vol.32 , pp. 2173-2182
    • Panacek, E.A.1    Marshall, J.C.2    Albertson, T.E.3    Johnson, D.H.4    Johnson, S.5    Macarthur, R.D.6    Miller, M.7    Barchuk, W.T.8    Fischkoff, S.9    Kaul, M.10
  • 10
    • 0037709808 scopus 로고    scopus 로고
    • Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial
    • Pafase ARDS Prevention Study Group. PMID:12794395
    • Schuster DP, Metzler M, Opal S, Lowry S, Balk R, Abraham E, Levy H, Slotman G, Coyne E, Souza S, et al.; Pafase ARDS Prevention Study Group. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med 2003; 31:1612-9 PMID:12794395. http://dx.doi.org/10.1097/01.CCM.0000063267.79824.DB
    • (2003) Crit Care Med , vol.31 , pp. 1612-1619
    • Schuster, D.P.1    Metzler, M.2    Opal, S.3    Lowry, S.4    Balk, R.5    Abraham, E.6    Levy, H.7    Slotman, G.8    Coyne, E.9    Souza, S.10
  • 11
    • 10744219506 scopus 로고    scopus 로고
    • Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, doubleblind, placebo-controlled, clinical trial
    • PMID:14758145
    • Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, et al.; Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, doubleblind, placebo-controlled, clinical trial. Crit Care Med 2004; 32:332-41 PMID:14758145 http://dx.doi.org/10.1097/01.CCM.0000108867.87890.6D
    • (2004) Crit Care Med , vol.32 , pp. 332-341
    • Opal, S.1    Laterre, P.F.2    Abraham, E.3    Francois, B.4    Wittebole, X.5    Lowry, S.6    Dhainaut, J.F.7    Warren, B.8    Dugernier, T.9    Lopez, A.10
  • 12
    • 84874886669 scopus 로고    scopus 로고
    • A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis
    • TLF LF-0801 Investigator Group. PMID:23425819
    • Guntupalli K, Dean N, Morris PE, Bandi V, Margolis B, Rivers E, Levy M, Lodato RF, Ismail PM, Reese A, et al.; TLF LF-0801 Investigator Group. A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit Care Med 2013; 41:706-16 PMID:23425819. http://dx.doi.org/10.1097/CCM.0b013e3182741551.
    • (2013) Crit Care Med , vol.41 , pp. 706-716
    • Guntupalli, K.1    Dean, N.2    Morris, P.E.3    Bandi, V.4    Margolis, B.5    Rivers, E.6    Levy, M.7    Lodato, R.F.8    Ismail, P.M.9    Reese, A.10
  • 13
    • 84891655610 scopus 로고    scopus 로고
    • halts phase II/III oasis trial in severe sepsis [Internet] 2012 [cited 2012 Feb 2] Available from
    • Agennix AG., Agennix AG halts phase II/III oasis trial in severe sepsis [Internet] 2012 [cited 2012 Feb 2] Available from:http://agennix.com/index.php?option=com_content&view=category&id=23&Itemid=102&lang=en
    • Agennix, A.G.1    Agennix, A.G.2
  • 14
    • 0035826096 scopus 로고    scopus 로고
    • Efficacy and safety of recombinant human activated protein C for severe sepsis
    • Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. PMID:11236773
    • Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al.; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709 PMID:11236773. http://dx.doi.org/10.1056/NEJM200103083441001.
    • (2001) N Engl J Med , vol.344 , pp. 699-709
    • Bernard, G.R.1    Vincent, J.L.2    Laterre, P.F.3    Larosa, S.P.4    Dhainaut, J.F.5    Lopez-Rodriguez, A.6    Steingrub, J.S.7    Garber, G.E.8    Helterbrand, J.D.9    Ely, E.W.10
  • 15
    • 25444492831 scopus 로고    scopus 로고
    • Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
    • Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. PMID:16192478
    • Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, et al.; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353:1332-41 PMID:16192478. http://dx.doi.org/10.1056/NEJMoa050935.
    • (2005) N Engl J Med , vol.353 , pp. 1332-1341
    • Abraham, E.1    Laterre, P.F.2    Garg, R.3    Levy, H.4    Talwar, D.5    Trzaskoma, B.L.6    François, B.7    Guy, J.S.8    Brückmann, M.9    Rea-Neto, A.10
  • 16
    • 33847687731 scopus 로고    scopus 로고
    • Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial
    • REsearching severe Sepsis and Organ dysfunction in children: A gLobal perspective (RESOLVE) study group. PMID:17350452
    • Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, et al.; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007; 369:836-43 PMID:17350452. http://dx.doi.org/10.1016/S0140-6736(07)60411-5.
    • (2007) Lancet , vol.369 , pp. 836-843
    • Nadel, S.1    Goldstein, B.2    Williams, M.D.3    Dalton, H.4    Peters, M.5    Macias, W.L.6    Abd-Allah, S.A.7    Levy, H.8    Angle, R.9    Wang, D.10
  • 18
    • 0037151571 scopus 로고    scopus 로고
    • Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock
    • PMID:12186604
    • Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-71 PMID:12186604. http://dx.doi.org/10.1001/jama.288.7.862.
    • (2002) JAMA , vol.288 , pp. 862-871
    • Annane, D.1    Sébille, V.2    Charpentier, C.3    Bollaert, P.E.4    François, B.5    Korach, J.M.6    Capellier, G.7    Cohen, Y.8    Azoulay, E.9    Troché, G.10
  • 20
    • 0029900294 scopus 로고    scopus 로고
    • Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein
    • The Soluble TNF Receptor Sepsis Study Group. PMID:8637514
    • Fisher CJ Jr., Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E; The Soluble TNF Receptor Sepsis Study Group. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996; 334:1697-702 PMID:8637514. http://dx.doi.org/10.1056/NEJM199606273342603.
    • (1996) N Engl J Med , vol.334 , pp. 1697-1702
    • Fisher Jr., C.J.1    Agosti, J.M.2    Opal, S.M.3    Lowry, S.F.4    Balk, R.A.5    Sadoff, J.C.6    Abraham, E.7    Schein, R.M.8    Benjamin, E.9
  • 21
    • 4444273012 scopus 로고    scopus 로고
    • Multiple-center, randomized, placebocontrolled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock
    • PMID:14707556
    • López A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, et al. Multiple-center, randomized, placebocontrolled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30 PMID:14707556. http://dx.doi.org/10.1097/01.CCM.0000105581.01815.C6.
    • (2004) Crit Care Med , vol.32 , pp. 21-30
    • López, A.1    Lorente, J.A.2    Steingrub, J.3    Bakker, J.4    McLuckie, A.5    Willatts, S.6    Brockway, M.7    Anzueto, A.8    Holzapfel, L.9    Breen, D.10
  • 22
    • 0028214566 scopus 로고
    • Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5
    • PMID:8143464
    • Marra MN, Thornton MB, Snable JL, Wilde CG, Scott RW. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit Care Med 1994; 22:559-65 PMID:8143464. http://dx.doi.org/10.1097/00003246-199404000-00009.
    • (1994) Crit Care Med , vol.22 , pp. 559-565
    • Marra, M.N.1    Thornton, M.B.2    Snable, J.L.3    Wilde, C.G.4    Scott, R.W.5
  • 23
    • 0027534545 scopus 로고
    • Protective effects of anti-O polysaccharide and anti-lipid A monoclonal antibodies on pulmonary hemodynamics
    • PMID:8444723
    • Chen TY, Warren HS, Greene E, Black KM, Frostell CG, Robinson DR, Zapol WM. Protective effects of anti-O polysaccharide and anti-lipid A monoclonal antibodies on pulmonary hemodynamics. J Appl Physiol 1993; 74:423-7 PMID:8444723.
    • (1993) J Appl Physiol , vol.74 , pp. 423-427
    • Chen, T.Y.1    Warren, H.S.2    Greene, E.3    Black, K.M.4    Frostell, C.G.5    Robinson, D.R.6    Zapol, W.M.7
  • 24
    • 53049091405 scopus 로고    scopus 로고
    • Animal models of sepsis and its complications
    • PMID:18827799
    • Fink MP. Animal models of sepsis and its complications. Kidney Int 2008; 74:991-3 PMID:18827799. http://dx.doi.org/10.1038/ki.2008.442.
    • (2008) Kidney Int , vol.74 , pp. 991-993
    • Fink, M.P.1
  • 25
    • 33646816044 scopus 로고    scopus 로고
    • Rodent models of intra-abdominal infection
    • PMID:16374368
    • Deitch EA. Rodent models of intra-abdominal infection. Shock 2005; 24(Suppl 1):19-23 PMID:16374368. http://dx.doi.org/10.1097/01.shk.0000191386.18818.0a
    • (2005) Shock , vol.24 , Issue.SUPPL. 1 , pp. 19-23
    • Deitch, E.A.1
  • 26
    • 0031606321 scopus 로고    scopus 로고
    • Animal models of sepsis and shock: A review and lessons learned
    • PMID:9466467
    • Deitch EA. Animal models of sepsis and shock: a review and lessons learned. Shock 1998; 9:1-11 PMID:9466467. http://dx.doi.org/10.1097/00024382-199801000-00001.
    • (1998) Shock , vol.9 , pp. 1-11
    • Deitch, E.A.1
  • 27
    • 70349705711 scopus 로고    scopus 로고
    • Animal models of sepsis and sepsis-induced kidney injury
    • PMID:19805915
    • Doi K, Leelahavanichkul A, Yuen PS, Star RA. Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest 2009; 119:2868-78 PMID:19805915. http://dx.doi.org/10.1172/JCI39421.
    • (2009) J Clin Invest , vol.119 , pp. 2868-2878
    • Doi, K.1    Leelahavanichkul, A.2    Yuen, P.S.3    Star, R.A.4
  • 28
    • 58849093274 scopus 로고    scopus 로고
    • Animal models of sepsis: Why does preclinical efficacy fail to translate to the clinical setting?
    • PMID:19104223
    • Dyson A, Singer M. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med 2009; 37(Suppl):S30-7 PMID:19104223. http://dx.doi.org/10.1097/CCM.0b013e3181922bd3.
    • (2009) Crit Care Med , vol.37 , Issue.SUPPL.
    • Dyson, A.1    Singer, M.2
  • 29
    • 70350519619 scopus 로고    scopus 로고
    • Animal models of sepsis. [vii-viii.]
    • vii-viii PMID:19892248
    • Zanotti-Cavazzoni SL, Goldfarb RD. Animal models of sepsis. [vii-viii.]. Crit Care Clin 2009; 25:703-19, vii-viii PMID:19892248. http://dx.doi.org/10.1016/j.ccc.2009.08.005.
    • (2009) Crit Care Clin , vol.25 , pp. 703-719
    • Zanotti-Cavazzoni, S.L.1    Goldfarb, R.D.2
  • 30
    • 0034778208 scopus 로고    scopus 로고
    • Animal models of sepsis
    • PMID:11680530
    • Freise H, Brückner UB, Spiegel HU. Animal models of sepsis. J Invest Surg 2001; 14:195-212 PMID:11680530. http://dx.doi.org/10.1080/089419301750420232.
    • (2001) J Invest Surg , vol.14 , pp. 195-212
    • Freise, H.1    Brückner, U.B.2    Spiegel, H.U.3
  • 31
    • 84869840966 scopus 로고    scopus 로고
    • Preclinical sepsis models
    • PMID:23046077
    • van der Poll T. Preclinical sepsis models. Surg Infect (Larchmt) 2012; 13:287-92 PMID:23046077. http://dx.doi.org/10.1089/sur.2012.105.
    • (2012) Surg Infect (Larchmt) , vol.13 , pp. 287-292
    • van der Poll, T.1
  • 32
    • 82755187765 scopus 로고    scopus 로고
    • LPS-induced cytokine production in human monocytes and macrophages
    • PMID:22142165
    • Rossol M, Heine H, Meusch U, Quandt D, Klein C, Sweet MJ, Hauschildt S. LPS-induced cytokine production in human monocytes and macrophages. Crit Rev Immunol 2011; 31:379-446 PMID:22142165. http://dx.doi.org/10.1615/CritRevImmunol.v31.i5.20.
    • (2011) Crit Rev Immunol , vol.31 , pp. 379-446
    • Rossol, M.1    Heine, H.2    Meusch, U.3    Quandt, D.4    Klein, C.5    Sweet, M.J.6    Hauschildt, S.7
  • 33
    • 77952525214 scopus 로고    scopus 로고
    • Lipid A receptor TLR4-mediated signaling pathways
    • PMID:20665200
    • Yamamoto M, Akira S. Lipid A receptor TLR4-mediated signaling pathways. Adv Exp Med Biol 2010; 667:59-68 PMID:20665200. http://dx.doi.org/10.1007/978-1-4419-1603-7_6.
    • (2010) Adv Exp Med Biol , vol.667 , pp. 59-68
    • Yamamoto, M.1    Akira, S.2
  • 34
    • 0033120081 scopus 로고    scopus 로고
    • Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: Evidence for TLR4 as the Lps gene product
    • PMID:10201887
    • Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162:3749-52 PMID:10201887.
    • (1999) J Immunol , vol.162 , pp. 3749-3752
    • Hoshino, K.1    Takeuchi, O.2    Kawai, T.3    Sanjo, H.4    Ogawa, T.5    Takeda, Y.6    Takeda, K.7    Akira, S.8
  • 35
    • 0018876276 scopus 로고
    • BCG-induced enhancement of endotoxin sensitivity in C3H/HeJ mice. I. In vivo studies
    • PMID:6154089
    • Vogel SN, Moore RN, Sipe JD, Rosenstreich DL. BCG-induced enhancement of endotoxin sensitivity in C3H/HeJ mice. I. In vivo studies. J Immunol 1980; 124:2004-9 PMID:6154089.
    • (1980) J Immunol , vol.124 , pp. 2004-2009
    • Vogel, S.N.1    Moore, R.N.2    Sipe, J.D.3    Rosenstreich, D.L.4
  • 36
    • 0014546925 scopus 로고
    • Genetic factors in leucocyte responses to endotoxin: Further studies in mice
    • PMID:4894397
    • Sultzer BM. Genetic factors in leucocyte responses to endotoxin: further studies in mice. J Immunol 1969; 103:32-8 PMID:4894397.
    • (1969) J Immunol , vol.103 , pp. 32-38
    • Sultzer, B.M.1
  • 37
    • 0017193690 scopus 로고
    • Significant contribution of spleen cells in mediating the lethal effects of endotoxin in vivo
    • PMID:965087
    • Glode LM, Mergenhagen SE, Rosenstreich DL. Significant contribution of spleen cells in mediating the lethal effects of endotoxin in vivo. Infect Immun 1976; 14:626-30 PMID:965087.
    • (1976) Infect Immun , vol.14 , pp. 626-630
    • Glode, L.M.1    Mergenhagen, S.E.2    Rosenstreich, D.L.3
  • 38
    • 0021136289 scopus 로고
    • Species differences in Kupffer cells and endotoxin sensitivity
    • PMID:6376358
    • McCuskey RS, McCuskey PA, Urbaschek R, Urbaschek B. Species differences in Kupffer cells and endotoxin sensitivity. Infect Immun 1984; 45:278-80 PMID:6376358.
    • (1984) Infect Immun , vol.45 , pp. 278-280
    • McCuskey, R.S.1    McCuskey, P.A.2    Urbaschek, R.3    Urbaschek, B.4
  • 40
    • 0029091068 scopus 로고
    • Influence of hypercortisolemia on soluble tumor necrosis factor receptor II and interleukin-1 receptor antagonist responses to endotoxin in human beings
    • discussion 410-1 PMID:7638758
    • Barber AE, Coyle SM, Fischer E, Smith C, van der Poll T, Shires GT, Lowry SF. Influence of hypercortisolemia on soluble tumor necrosis factor receptor II and interleukin-1 receptor antagonist responses to endotoxin in human beings. Surgery 1995; 118:406-10, discussion 410-1 PMID:7638758. http://dx.doi.org/10.1016/S0039-6060(05)80352-6.
    • (1995) Surgery , vol.118 , pp. 406-410
    • Barber, A.E.1    Coyle, S.M.2    Fischer, E.3    Smith, C.4    van der Poll, T.5    Shires, G.T.6    Lowry, S.F.7
  • 41
    • 0028811230 scopus 로고
    • Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration
    • PMID:7594512
    • Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995; 155:5038-45 PMID:7594512.
    • (1995) J Immunol , vol.155 , pp. 5038-5045
    • Suffredini, A.F.1    Reda, D.2    Banks, S.M.3    Tropea, M.4    Agosti, J.M.5    Miller, R.6
  • 42
    • 0027210486 scopus 로고
    • Brief report: Shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin
    • PMID:8479465
    • Taveira da Silva AM, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL. Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 1993; 328:1457-60 PMID:8479465. http://dx.doi.org/10.1056/NEJM199305203282005.
    • (1993) N Engl J Med , vol.328 , pp. 1457-1460
    • Taveira da Silva, A.M.1    Kaulbach, H.C.2    Chuidian, F.S.3    Lambert, D.R.4    Suffredini, A.F.5    Danner, R.L.6
  • 44
    • 69449086963 scopus 로고    scopus 로고
    • Hemopexin down-regulates LPSinduced proinflammatory cytokines from macrophages
    • PMID:19395472
    • Liang X, Lin T, Sun G, Beasley-Topliffe L, Cavaillon JM, Warren HS. Hemopexin down-regulates LPSinduced proinflammatory cytokines from macrophages. J Leukoc Biol 2009; 86:229-35 PMID:19395472. http://dx.doi.org/10.1189/jlb.1208742.
    • (2009) J Leukoc Biol , vol.86 , pp. 229-235
    • Liang, X.1    Lin, T.2    Sun, G.3    Beasley-Topliffe, L.4    Cavaillon, J.M.5    Warren, H.S.6
  • 45
    • 84874457770 scopus 로고    scopus 로고
    • Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases
    • PMID:23401516
    • Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, et al.; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013; 110:3507-12 PMID:23401516. http://dx.doi.org/10.1073/pnas.1222878110.
    • (2013) Proc Natl Acad Sci U S A , vol.110 , pp. 3507-3512
    • Seok, J.1    Warren, H.S.2    Cuenca, A.G.3    Mindrinos, M.N.4    Baker, H.V.5    Xu, W.6    Richards, D.R.7    McDonald-Smith, G.P.8    Gao, H.9    Hennessy, L.10
  • 46
    • 84879112607 scopus 로고    scopus 로고
    • Of men, not mice, PMID:23558605
    • Of men, not mice. Nat Med 2013; 19:379 PMID:23558605. http://dx.doi.org/10.1038/nm.3163.
    • (2013) Nat Med , vol.19 , pp. 379
  • 47
    • 84868113158 scopus 로고    scopus 로고
    • Scavenger receptor class a plays a central role in mediating mortality and the development of the proinflammatory phenotype in polymicrobial sepsis
    • PMID:23071440
    • Ozment TR, Ha T, Breuel KF, Ford TR, Ferguson DA, Kalbfleisch J, Schweitzer JB, Kelley JL, Li C, Williams DL. Scavenger receptor class a plays a central role in mediating mortality and the development of the proinflammatory phenotype in polymicrobial sepsis. PLoS Pathog 2012; 8:e1002967 PMID:23071440. http://dx.doi.org/10.1371/journal.ppat.1002967.
    • (2012) PLoS Pathog , vol.8
    • Ozment, T.R.1    Ha, T.2    Breuel, K.F.3    Ford, T.R.4    Ferguson, D.A.5    Kalbfleisch, J.6    Schweitzer, J.B.7    Kelley, J.L.8    Li, C.9    Williams, D.L.10
  • 49
    • 0035447007 scopus 로고    scopus 로고
    • Characterization of a hyperdynamic murine model of resuscitated sepsis using echocardiography
    • PMID:11549551
    • Hollenberg SM, Dumasius A, Easington C, Colilla SA, Neumann A, Parrillo JE. Characterization of a hyperdynamic murine model of resuscitated sepsis using echocardiography. Am J Respir Crit Care Med 2001; 164:891-5 PMID:11549551. http://dx.doi.org/10.1164/ajrccm.164.5.2010073.
    • (2001) Am J Respir Crit Care Med , vol.164 , pp. 891-895
    • Hollenberg, S.M.1    Dumasius, A.2    Easington, C.3    Colilla, S.A.4    Neumann, A.5    Parrillo, J.E.6
  • 50
    • 1242342723 scopus 로고    scopus 로고
    • Antibiotics delay but do not prevent bacteremia and lung injury in murine sepsis
    • PMID:14758168
    • Doerschug KC, Powers LS, Monick MM, Thorne PS, Hunninghake GW. Antibiotics delay but do not prevent bacteremia and lung injury in murine sepsis. Crit Care Med 2004; 32:489-94 PMID:14758168. http://dx.doi.org/10.1097/01.CCM.0000109450.66450.23.
    • (2004) Crit Care Med , vol.32 , pp. 489-494
    • Doerschug, K.C.1    Powers, L.S.2    Monick, M.M.3    Thorne, P.S.4    Hunninghake, G.W.5
  • 51
    • 0026585007 scopus 로고
    • Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia
    • PMID:1315357
    • Eskandari MK, Bolgos G, Miller C, Nguyen DT, DeForge LE, Remick DG. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J Immunol 1992; 148:2724-30 PMID:1315357.
    • (1992) J Immunol , vol.148 , pp. 2724-2730
    • Eskandari, M.K.1    Bolgos, G.2    Miller, C.3    Nguyen, D.T.4    Deforge, L.E.5    Remick, D.G.6
  • 54
    • 0038481984 scopus 로고    scopus 로고
    • A critical role of leukotriene B4 in neutrophil migration to infectious focus in cecal ligaton and puncture sepsis
    • PMID:12558146
    • Rios-Santos F, Benjamim CF, Zavery D, Ferreira SH, Cunha Fde Q. A critical role of leukotriene B4 in neutrophil migration to infectious focus in cecal ligaton and puncture sepsis. Shock 2003; 19:61-5 PMID:12558146. http://dx.doi.org/10.1097/00024382-200301000-00012.
    • (2003) Shock , vol.19 , pp. 61-65
    • Rios-Santos, F.1    Benjamim, C.F.2    Zavery, D.3    Ferreira, S.H.4    Cunha Fde, Q.5
  • 56
    • 0034958947 scopus 로고    scopus 로고
    • Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
    • PMID:11445675
    • Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-10 PMID:11445675. http://dx.doi.org/10.1097/00003246-200107000-00002.
    • (2001) Crit Care Med , vol.29 , pp. 1303-1310
    • Angus, D.C.1    Linde-Zwirble, W.T.2    Lidicker, J.3    Clermont, G.4    Carcillo, J.5    Pinsky, M.R.6
  • 57
    • 0142249406 scopus 로고    scopus 로고
    • Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice
    • PMID:14531793
    • Miyaji T, Hu X, Yuen PS, Muramatsu Y, Iyer S, Hewitt SM, Star RA. Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int 2003; 64:1620-31 PMID:14531793. http://dx.doi.org/10.1046/j.1523-1755.2003.00268.x
    • (2003) Kidney Int , vol.64 , pp. 1620-1631
    • Miyaji, T.1    Hu, X.2    Yuen, P.S.3    Muramatsu, Y.4    Iyer, S.5    Hewitt, S.M.6    Star, R.A.7
  • 58
    • 69449084286 scopus 로고    scopus 로고
    • Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice
    • PMID:19369639
    • Unsinger J, McDonough JS, Shultz LD, Ferguson TA, Hotchkiss RS. Sepsis-induced human lymphocyte apoptosis and cytokine production in "humanized" mice. J Leukoc Biol 2009; 86:219-27 PMID:19369639. http://dx.doi.org/10.1189/jlb.1008615.
    • (2009) J Leukoc Biol , vol.86 , pp. 219-227
    • Unsinger, J.1    McDonough, J.S.2    Shultz, L.D.3    Ferguson, T.A.4    Hotchkiss, R.S.5
  • 59
    • 0031934850 scopus 로고    scopus 로고
    • Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis
    • PMID:9498446
    • Camerota AJ, Creasey AA, Patla V, Larkin VA, Fink MP. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis. J Infect Dis 1998; 177:668-76 PMID:9498446. http://dx.doi.org/10.1086/514246.
    • (1998) J Infect Dis , vol.177 , pp. 668-676
    • Camerota, A.J.1    Creasey, A.A.2    Patla, V.3    Larkin, V.A.4    Fink, M.P.5
  • 60
    • 0038690407 scopus 로고    scopus 로고
    • Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial
    • OPTIMIST Trial Study Group. PMID:12851279
    • Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez AL, Beale R, Svoboda P, Laterre PF, Simon S, et al.; OPTIMIST Trial Study Group. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290:238-47 PMID:12851279. http://dx.doi.org/10.1001/jama.290.2.238.
    • (2003) JAMA , vol.290 , pp. 238-247
    • Abraham, E.1    Reinhart, K.2    Opal, S.3    Demeyer, I.4    Doig, C.5    Rodriguez, A.L.6    Beale, R.7    Svoboda, P.8    Laterre, P.F.9    Simon, S.10
  • 61
    • 0035159740 scopus 로고    scopus 로고
    • Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study
    • PMID:11700399
    • Abraham E, Reinhart K, Svoboda P, Seibert A, Olthoff D, Dal Nogare A, Postier R, Hempelmann G, Butler T, Martin E, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29:2081-9 PMID:11700399. http://dx.doi.org/10.1097/00003246-200111000-00007.
    • (2001) Crit Care Med , vol.29 , pp. 2081-2089
    • Abraham, E.1    Reinhart, K.2    Svoboda, P.3    Seibert, A.4    Olthoff, D.5    Dal Nogare, A.6    Postier, R.7    Hempelmann, G.8    Butler, T.9    Martin, E.10
  • 64
    • 0033963267 scopus 로고    scopus 로고
    • Noradrenaline and nomega-monomethyl-L-arginine (L-NMMA): Effects on haemodynamics and regional blood flow in healthy and septic sheep
    • PMID:10657275
    • Booke M, Hinder F, McGuire R, Traber LD, Traber DL. Noradrenaline and nomega-monomethyl-L-arginine (L-NMMA): effects on haemodynamics and regional blood flow in healthy and septic sheep. Clin Sci (Lond) 2000; 98:193-200 PMID:10657275. http://dx.doi.org/10.1042/CS19990143.
    • (2000) Clin Sci (Lond) , vol.98 , pp. 193-200
    • Booke, M.1    Hinder, F.2    McGuire, R.3    Traber, L.D.4    Traber, D.L.5
  • 65
    • 0019817114 scopus 로고
    • Effectiveness of steroid/antibiotic treatment in primates administered LD100 Escherichia coli
    • PMID:7018430
    • Hinshaw LB, Beller-Todd BK, Archer LT, Benjamin B, Flournoy DJ, Passey R, Wilson MF. Effectiveness of steroid/antibiotic treatment in primates administered LD100 Escherichia coli. Ann Surg 1981; 194:51-6 PMID:7018430. http://dx.doi.org/10.1097/00000658-198107000-00009.
    • (1981) Ann Surg , vol.194 , pp. 51-56
    • Hinshaw, L.B.1    Beller-Todd, B.K.2    Archer, L.T.3    Benjamin, B.4    Flournoy, D.J.5    Passey, R.6    Wilson, M.F.7
  • 66
    • 0035146571 scopus 로고    scopus 로고
    • The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis
    • PMID:11176151
    • Opal SM, Palardy JE, Parejo NA, Creasey AA. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit Care Med 2001; 29:13-7 PMID:11176151. http://dx.doi.org/10.1097/00003246-200101000-00003.
    • (2001) Crit Care Med , vol.29 , pp. 13-17
    • Opal, S.M.1    Palardy, J.E.2    Parejo, N.A.3    Creasey, A.A.4
  • 67
    • 0026016470 scopus 로고
    • Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial
    • The HA-1A Sepsis Study Group, PMID:1988827
    • Ziegler EJ, Fisher CJ Jr., Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324:429-36 PMID:1988827. http://dx.doi.org/10.1056/NEJM199102143240701.
    • (1991) N Engl J Med , vol.324 , pp. 429-436
    • Ziegler, E.J.1    Fisher Jr., C.J.2    Sprung, C.L.3    Straube, R.C.4    Sadoff, J.C.5    Foulke, G.E.6    Wortel, C.H.7    Fink, M.P.8    Dellinger, R.P.9    Teng, N.N.10
  • 68
    • 0025917510 scopus 로고
    • A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis
    • The XOMA Sepsis Study Group. PMID:1865542
    • Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, et al.; The XOMA Sepsis Study Group. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991; 266:1097-102 PMID:1865542. http://dx.doi.org/10.1001/jama.1991.03470080067031.
    • (1991) JAMA , vol.266 , pp. 1097-1102
    • Greenman, R.L.1    Schein, R.M.2    Martin, M.A.3    Wenzel, R.P.4    Macintyre, N.R.5    Emmanuel, G.6    Chmel, H.7    Kohler, R.B.8    McCarthy, M.9    Plouffe, J.10
  • 69
    • 0029043636 scopus 로고
    • A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial
    • The E5 Sepsis Study Group, PMID:7774238
    • Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, Quenzer RW, Iberti TJ, Macintyre N, Schein RM. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 1995; 23:994-1006 PMID:7774238. http://dx.doi.org/10.1097/00003246-199506000-00003.
    • (1995) Crit Care Med , vol.23 , pp. 994-1006
    • Bone, R.C.1    Balk, R.A.2    Fein, A.M.3    Perl, T.M.4    Wenzel, R.P.5    Reines, H.D.6    Quenzer, R.W.7    Iberti, T.J.8    Macintyre, N.9    Schein, R.M.10
  • 70
    • 0034607323 scopus 로고    scopus 로고
    • E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: A randomized controlled trial. E5 Study Investigators
    • PMID:10755499
    • Angus DC, Birmingham MC, Balk RA, Scannon PJ, Collins D, Kruse JA, Graham DR, Dedhia HV, Homann S, MacIntyre N. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. JAMA 2000; 283:1723-30 PMID:10755499. http://dx.doi.org/10.1001/jama.283.13.1723.
    • (2000) JAMA , vol.283 , pp. 1723-1730
    • Angus, D.C.1    Birmingham, M.C.2    Balk, R.A.3    Scannon, P.J.4    Collins, D.5    Kruse, J.A.6    Graham, D.R.7    Dedhia, H.V.8    Homann, S.9    Macintyre, N.10
  • 71
    • 0037326716 scopus 로고    scopus 로고
    • Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis
    • MAB-T88 Sepsis Study Group. PMID:12576946
    • Albertson TE, Panacek EA, MacArthur RD, Johnson SB, Benjamin E, Matuschak GM, Zaloga G, Maki D, Silverstein J, Tobias JK, et al.; MAB-T88 Sepsis Study Group. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis. Crit Care Med 2003; 31:419-27 PMID:12576946 http://dx.doi.org/10.1097/01.CCM.0000045564.51812.3F
    • (2003) Crit Care Med , vol.31 , pp. 419-427
    • Albertson, T.E.1    Panacek, E.A.2    Macarthur, R.D.3    Johnson, S.B.4    Benjamin, E.5    Matuschak, G.M.6    Zaloga, G.7    Maki, D.8    Silverstein, J.9    Tobias, J.K.10
  • 72
    • 0034675328 scopus 로고    scopus 로고
    • Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial
    • rBPI21 Meningococcal Sepsis Study Group, PMID:11041396
    • Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, Yeh T, Kim SS, Cafaro DP, Scannon PJ, et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 2000; 356:961-7 PMID:11041396. http://dx.doi.org/10.1016/S0140-6736(00)02712-4.
    • (2000) Lancet , vol.356 , pp. 961-967
    • Levin, M.1    Quint, P.A.2    Goldstein, B.3    Barton, P.4    Bradley, J.S.5    Shemie, S.D.6    Yeh, T.7    Kim, S.S.8    Cafaro, D.P.9    Scannon, P.J.10
  • 73
    • 8244235133 scopus 로고    scopus 로고
    • p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial
    • Ro 45-2081 Study Group, PMID:9153367
    • Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997; 277:1531-8 PMID:9153367. http://dx.doi.org/10.1001/jama.1997.03540430043031.
    • (1997) JAMA , vol.277 , pp. 1531-1538
    • Abraham, E.1    Glauser, M.P.2    Butler, T.3    Garbino, J.4    Gelmont, D.5    Laterre, P.F.6    Kudsk, K.7    Bruining, H.A.8    Otto, C.9    Tobin, E.10
  • 74
    • 0035100346 scopus 로고    scopus 로고
    • Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients
    • Lenercept Study Group. PMID:11373411
    • Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, Margolis B, Kudsk K, Zimmerli W, Anderson P, et al.; Lenercept Study Group. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29:503-10 PMID:11373411. http://dx.doi.org/10.1097/00003246-200103000-00006.
    • (2001) Crit Care Med , vol.29 , pp. 503-510
    • Abraham, E.1    Laterre, P.F.2    Garbino, J.3    Pingleton, S.4    Butler, T.5    Dugernier, T.6    Margolis, B.7    Kudsk, K.8    Zimmerli, W.9    Anderson, P.10
  • 75
    • 0028957549 scopus 로고
    • Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial
    • TNFalpha MAb Sepsis Study Group, PMID:7884952
    • Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNFalpha MAb Sepsis Study Group. JAMA 1995; 273:934-41 PMID:7884952. http://dx.doi.org/10.1001/jama.1995.03520360048038.
    • (1995) JAMA , vol.273 , pp. 934-941
    • Abraham, E.1    Wunderink, R.2    Silverman, H.3    Perl, T.M.4    Nasraway, S.5    Levy, H.6    Bone, R.7    Wenzel, R.P.8    Balk, R.9    Allred, R.10
  • 76
    • 0029835023 scopus 로고    scopus 로고
    • INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis
    • International Sepsis Trial Study Group, PMID:8797612
    • Cohen J, Carlet J; International Sepsis Trial Study Group. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. Crit Care Med 1996; 24:1431-40 PMID:8797612. http://dx.doi.org/10.1097/00003246-199609000-00002.
    • (1996) Crit Care Med , vol.24 , pp. 1431-1440
    • Cohen, J.1    Carlet, J.2
  • 77
    • 0032495658 scopus 로고    scopus 로고
    • Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock
    • NORASEPT II Study Group. PMID:9734938
    • Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, et al.; NORASEPT II Study Group. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998; 351:929-33 PMID:9734938.
    • (1998) Lancet , vol.351 , pp. 929-933
    • Abraham, E.1    Anzueto, A.2    Gutierrez, G.3    Tessler, S.4    San Pedro, G.5    Wunderink, R.6    Dal Nogare, A.7    Nasraway, S.8    Berman, S.9    Cooney, R.10
  • 78
    • 33747502519 scopus 로고    scopus 로고
    • Safety and efficacy of affinitypurified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis
    • PMID:16810105
    • Rice TW, Wheeler AP, Morris PE, Paz HL, Russell JA, Edens TR, Bernard GR. Safety and efficacy of affinitypurified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis. Crit Care Med 2006; 34:2271-81 PMID:16810105. http://dx.doi.org/10.1097/01.CCM.0000230385.82679.34.
    • (2006) Crit Care Med , vol.34 , pp. 2271-2281
    • Rice, T.W.1    Wheeler, A.P.2    Morris, P.E.3    Paz, H.L.4    Russell, J.A.5    Edens, T.R.6    Bernard, G.R.7
  • 79
    • 9344246862 scopus 로고    scopus 로고
    • Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
    • PMID:8706447
    • Reinhart K, Wiegand-Löhnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24:733-42 PMID:8706447. http://dx.doi.org/10.1097/00003246-199605000-00003.
    • (1996) Crit Care Med , vol.24 , pp. 733-742
    • Reinhart, K.1    Wiegand-Löhnert, C.2    Grimminger, F.3    Kaul, M.4    Withington, S.5    Treacher, D.6    Eckart, J.7    Willatts, S.8    Bouza, C.9    Krausch, D.10
  • 80
    • 0035046049 scopus 로고    scopus 로고
    • Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study
    • PMID:11373466
    • Reinhart K, Menges T, Gardlund B, Harm Zwaveling J, Smithes M, Vincent JL, Tellado JM, Salgado-Remigio A, Zimlichman R, Withington S, et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 2001; 29:765-9 PMID:11373466. http://dx.doi.org/10.1097/00003246-200104000-00015.
    • (2001) Crit Care Med , vol.29 , pp. 765-769
    • Reinhart, K.1    Menges, T.2    Gardlund, B.3    Harm Zwaveling, J.4    Smithes, M.5    Vincent, J.L.6    Tellado, J.M.7    Salgado-Remigio, A.8    Zimlichman, R.9    Withington, S.10
  • 81
    • 0029132699 scopus 로고
    • CDP571, a humanized antibody to human tumor necrosis factor-alpha: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock
    • CPD571 Sepsis Study Group, PMID:7664546
    • Dhainaut JF, Vincent JL, Richard C, Lejeune P, Martin C, Fierobe L, Stephens S, Ney UM, Sopwith M. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 1995; 23:1461-9 PMID:7664546. http://dx.doi.org/10.1097/00003246-199509000-00004.
    • (1995) Crit Care Med , vol.23 , pp. 1461-1469
    • Dhainaut, J.F.1    Vincent, J.L.2    Richard, C.3    Lejeune, P.4    Martin, C.5    Fierobe, L.6    Stephens, S.7    Ney, U.M.8    Sopwith, M.9
  • 82
    • 0027406403 scopus 로고
    • Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis
    • The CB0006 Sepsis Syndrome Study Group, PMID:8440099
    • Fisher CJ Jr., Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P, Harris SJ, Schein RM, Panacek EA, Vincent JL, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21:318-27 PMID:8440099. http://dx.doi.org/10.1097/00003246-199303000-00006.
    • (1993) Crit Care Med , vol.21 , pp. 318-327
    • Fisher Jr., C.J.1    Opal, S.M.2    Dhainaut, J.F.3    Stephens, S.4    Zimmerman, J.L.5    Nightingale, P.6    Harris, S.J.7    Schein, R.M.8    Panacek, E.A.9    Vincent, J.L.10
  • 83
    • 0027945044 scopus 로고
    • Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial
    • BN 52021 Sepsis Study Group, PMID:7956274
    • Dhainaut JF, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet JP, Wolff M, Holzapfel L, Zeni F, Dreyfuss D, Mira JP, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 1994; 22:1720-8 PMID:7956274.
    • (1994) Crit Care Med , vol.22 , pp. 1720-1728
    • Dhainaut, J.F.1    Tenaillon, A.2    Le Tulzo, Y.3    Schlemmer, B.4    Solet, J.P.5    Wolff, M.6    Holzapfel, L.7    Zeni, F.8    Dreyfuss, D.9    Mira, J.P.10
  • 84
    • 0032433468 scopus 로고    scopus 로고
    • Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial
    • BN 52021 Sepsis Investigator Group, PMID:9875905
    • Dhainaut JF, Tenaillon A, Hemmer M, Damas P, Le Tulzo Y, Radermacher P, Schaller MD, Sollet JP, Wolff M, Holzapfel L, et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit Care Med 1998; 26:1963-71 PMID:9875905. http://dx.doi.org/10.1097/00003246-199812000-00021.
    • (1998) Crit Care Med , vol.26 , pp. 1963-1971
    • Dhainaut, J.F.1    Tenaillon, A.2    Hemmer, M.3    Damas, P.4    Le Tulzo, Y.5    Radermacher, P.6    Schaller, M.D.7    Sollet, J.P.8    Wolff, M.9    Holzapfel, L.10
  • 85
    • 0000918029 scopus 로고    scopus 로고
    • Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis
    • PMID:10752807
    • Vincent JL, Spapen H, Bakker J, Webster NR, Curtis L. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit Care Med 2000; 28:638-42 PMID:10752807. http://dx.doi.org/10.1097/00003246-200003000-00006.
    • (2000) Crit Care Med , vol.28 , pp. 638-642
    • Vincent, J.L.1    Spapen, H.2    Bakker, J.3    Webster, N.R.4    Curtis, L.5
  • 87
    • 0030133079 scopus 로고    scopus 로고
    • Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: A prospective, multi-center, double-blind, randomized phase II trial
    • PMID:9156785
    • Froon AM, Greve JW, Buurman WA, van der Linden CJ, Langemeijer HJ, Ulrich C, Bourgeois M. Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomized phase II trial. Shock 1996; 5:313-9 PMID:9156785. http://dx.doi.org/10.1097/00024382-199605000-00001.
    • (1996) Shock , vol.5 , pp. 313-319
    • Froon, A.M.1    Greve, J.W.2    Buurman, W.A.3    van der Linden, C.J.4    Langemeijer, H.J.5    Ulrich, C.6    Bourgeois, M.7
  • 88
    • 0034304768 scopus 로고    scopus 로고
    • Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: A prospective, multicenter, double-blind, randomized phase II trial
    • TCV-309 Septic Shock Study Group, PMID:11049104
    • Poeze M, Froon AH, Ramsay G, Buurman WA, Greve JW. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group. Shock 2000; 14:421-8 PMID:11049104. http://dx.doi.org/10.1097/00024382-200014040-00001.
    • (2000) Shock , vol.14 , pp. 421-428
    • Poeze, M.1    Froon, A.H.2    Ramsay, G.3    Buurman, W.A.4    Greve, J.W.5
  • 90
    • 74049125175 scopus 로고    scopus 로고
    • Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis
    • Eritoran Sepsis Study Group, PMID:19661804
    • Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, Wheeler J, Gogate J, Opal SM; Eritoran Sepsis Study Group. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010; 38:72-83 PMID:19661804. http://dx.doi.org/10.1097/CCM.0b013e3181b07b78.
    • (2010) Crit Care Med , vol.38 , pp. 72-83
    • Tidswell, M.1    Tillis, W.2    Larosa, S.P.3    Lynn, M.4    Wittek, A.E.5    Kao, R.6    Wheeler, J.7    Gogate, J.8    Opal, S.M.9
  • 91
    • 84875124740 scopus 로고    scopus 로고
    • Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: The ACCESS randomized trial
    • ACCESS Study Group. PMID:23512062
    • Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, et al.; ACCESS Study Group. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013; 309:1154-62 PMID:23512062. http://dx.doi.org/10.1001/jama.2013.2194.
    • (2013) JAMA , vol.309 , pp. 1154-1162
    • Opal, S.M.1    Laterre, P.F.2    Francois, B.3    Larosa, S.P.4    Angus, D.C.5    Mira, J.P.6    Wittebole, X.7    Dugernier, T.8    Perrotin, D.9    Tidswell, M.10
  • 92
    • 84883615933 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled, phase-2B study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation
    • Forthcoming
    • Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, Hoste E, Levy H, Hirman J, Levi M, et al. A randomized, double-blind, placebo-controlled, phase-2B study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013; (Forthcoming)
    • (2013) Crit Care Med
    • Vincent, J.L.1    Ramesh, M.K.2    Ernest, D.3    Larosa, S.P.4    Pachl, J.5    Aikawa, N.6    Hoste, E.7    Levy, H.8    Hirman, J.9    Levi, M.10
  • 93
    • 73449108032 scopus 로고    scopus 로고
    • Lipid Infusion and Patient Outcomes in Sepsis (LIPOS) Investigators. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: Results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial
    • PMID:19770753
    • Dellinger RP, Tomayko JF, Angus DC, Opal S, Cupo MA, McDermott S, Ducher A, Calandra T, Cohen J; Lipid Infusion and Patient Outcomes in Sepsis (LIPOS) Investigators. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial. Crit Care Med 2009; 37:2929-38 PMID:19770753 http://dx.doi.org/10.1097/CCM.0b013e3181b0266c
    • (2009) Crit Care Med , vol.37 , pp. 2929-2938
    • Dellinger, R.P.1    Tomayko, J.F.2    Angus, D.C.3    Opal, S.4    Cupo, M.A.5    McDermott, S.6    Ducher, A.7    Calandra, T.8    Cohen, J.9
  • 94
    • 0008021312 scopus 로고    scopus 로고
    • Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial
    • CP-0127 SIRS and Sepsis Study Group, PMID:9020273
    • Fein AM, Bernard GR, Criner GJ, Fletcher EC, Good JT Jr., Knaus WA, Levy H, Matuschak GM, Shanies HM, Taylor RW, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 1997; 277:482-7 PMID:9020273. http://dx.doi.org/10.1001/jama.1997.03540300050033.
    • (1997) JAMA , vol.277 , pp. 482-487
    • Fein, A.M.1    Bernard, G.R.2    Criner, G.J.3    Fletcher, E.C.4    Good Jr., J.T.5    Knaus, W.A.6    Levy, H.7    Matuschak, G.M.8    Shanies, H.M.9    Taylor, R.W.10
  • 97
    • 0027171963 scopus 로고
    • Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation
    • PMID:8365305
    • Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104:882-8 PMID:8365305. http://dx.doi.org/10.1378/chest.104.3.882.
    • (1993) Chest , vol.104 , pp. 882-888
    • Fourrier, F.1    Chopin, C.2    Huart, J.J.3    Runge, I.4    Caron, C.5    Goudemand, J.6
  • 98
    • 0031825290 scopus 로고    scopus 로고
    • Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebocontrolled, double-blind trials with antithrombin III in severe sepsis
    • PMID:9722035
    • Eisele B, Lamy M, Thijs LG, Keinecke HO, Schuster HP, Matthias FR, Fourrier F, Heinrichs H, Delvos U. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebocontrolled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998; 24:663-72 PMID:9722035. http://dx.doi.org/10.1007/s001340050642.
    • (1998) Intensive Care Med , vol.24 , pp. 663-672
    • Eisele, B.1    Lamy, M.2    Thijs, L.G.3    Keinecke, H.O.4    Schuster, H.P.5    Matthias, F.R.6    Fourrier, F.7    Heinrichs, H.8    Delvos, U.9
  • 99
    • 7144251856 scopus 로고    scopus 로고
    • Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: A controlled double-blind, randomized, multicenter study
    • PMID:9609411
    • Baudo F, Caimi TM, de Cataldo F, Ravizza A, Arlati S, Casella G, Carugo D, Palareti G, Legnani C, Ridolfi L, et al. Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998; 24:336-42 PMID:9609411. http://dx.doi.org/10.1007/s001340050576.
    • (1998) Intensive Care Med , vol.24 , pp. 336-342
    • Baudo, F.1    Caimi, T.M.2    de Cataldo, F.3    Ravizza, A.4    Arlati, S.5    Casella, G.6    Carugo, D.7    Palareti, G.8    Legnani, C.9    Ridolfi, L.10
  • 100
    • 0035904368 scopus 로고    scopus 로고
    • Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial
    • KyberSept Trial Study Group. PMID:11597289
    • Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Pénzes I, Kübler A, et al.; KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286:1869-78 PMID:11597289. http://dx.doi.org/10.1001/jama.286.15.1869.
    • (2001) JAMA , vol.286 , pp. 1869-1878
    • Warren, B.L.1    Eid, A.2    Singer, P.3    Pillay, S.S.4    Carl, P.5    Novak, I.6    Chalupa, P.7    Atherstone, A.8    Pénzes, I.9    Kübler, A.10
  • 101
  • 102
    • 0023252009 scopus 로고
    • A controlled clinical trial of highdose methylprednisolone in the treatment of severe sepsis and septic shock
    • PMID:3306374
    • Bone RC, Fisher CJ Jr., Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of highdose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653-8 PMID:3306374. http://dx.doi.org/10.1056/NEJM198709103171101.
    • (1987) N Engl J Med , vol.317 , pp. 653-658
    • Bone, R.C.1    Fisher Jr., C.J.2    Clemmer, T.P.3    Slotman, G.J.4    Metz, C.A.5    Balk, R.A.6
  • 103
    • 0031942028 scopus 로고    scopus 로고
    • Reversal of late septic shock with supraphysiologic doses of hydrocortisone
    • PMID:9559600
    • Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26:645-50 PMID:9559600. http://dx.doi.org/10.1097/00003246-199804000-00010.
    • (1998) Crit Care Med , vol.26 , pp. 645-650
    • Bollaert, P.E.1    Charpentier, C.2    Levy, B.3    Debouverie, M.4    Audibert, G.5    Larcan, A.6
  • 104
    • 27944471374 scopus 로고    scopus 로고
    • Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock
    • PMID:16276166
    • Oppert M, Schindler R, Husung C, Offermann K, Gräf KJ, Boenisch O, Barckow D, Frei U, Eckardt KU. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 2005; 33:2457-64 PMID:16276166. http://dx.doi.org/10.1097/01. CCM.0000186370.78639.23.
    • (2005) Crit Care Med , vol.33 , pp. 2457-2464
    • Oppert, M.1    Schindler, R.2    Husung, C.3    Offermann, K.4    Gräf, K.J.5    Boenisch, O.6    Barckow, D.7    Frei, U.8    Eckardt, K.U.9
  • 106
    • 0032946372 scopus 로고    scopus 로고
    • Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study
    • PMID:10321661
    • Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27:723-32 PMID:10321661. http://dx.doi.org/10.1097/00003246-199904000-00025.
    • (1999) Crit Care Med , vol.27 , pp. 723-732
    • Briegel, J.1    Forst, H.2    Haller, M.3    Schelling, G.4    Kilger, E.5    Kuprat, G.6    Hemmer, B.7    Hummel, T.8    Lenhart, A.9    Heyduck, M.10
  • 107
    • 0037323852 scopus 로고    scopus 로고
    • Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis
    • Pneumonia Sepsis Study Group. PMID:12576938
    • Root RK, Lodato RF, Patrick W, Cade JF, Fotheringham N, Milwee S, Vincent JL, Torres A, Rello J, Nelson S; Pneumonia Sepsis Study Group. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 2003; 31:367-73 PMID:12576938. http://dx.doi.org/10.1097/01.CCM.0000048629.32625.5D
    • (2003) Crit Care Med , vol.31 , pp. 367-373
    • Root, R.K.1    Lodato, R.F.2    Patrick, W.3    Cade, J.F.4    Fotheringham, N.5    Milwee, S.6    Vincent, J.L.7    Torres, A.8    Rello, J.9    Nelson, S.10
  • 108
    • 0037099153 scopus 로고    scopus 로고
    • A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction
    • PMID:12119223
    • Presneill JJ, Harris T, Stewart AG, Cade JF, Wilson JW. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002; 166:138-43 PMID:12119223. http://dx.doi.org/10.1164/rccm.2009005.
    • (2002) Am J Respir Crit Care Med , vol.166 , pp. 138-143
    • Presneill, J.J.1    Harris, T.2    Stewart, A.G.3    Cade, J.F.4    Wilson, J.W.5
  • 109
    • 33244495095 scopus 로고    scopus 로고
    • Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: A randomized, doubleblind, placebo-controlled clinical trial
    • discussion 154 PMID:16490891
    • Orozco H, Arch J, Medina-Franco H, Pantoja JP, González QH, Vilatoba M, Hinojosa C, Vargas-Vorackova F, Sifuentes-Osornio J. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, doubleblind, placebo-controlled clinical trial. Arch Surg 2006; 141:150-3, discussion 154 PMID:16490891. http://dx.doi.org/10.1001/archsurg.141.2.150.
    • (2006) Arch Surg , vol.141 , pp. 150-153
    • Orozco, H.1    Arch, J.2    Medina-Franco, H.3    Pantoja, J.P.4    González, Q.H.5    Vilatoba, M.6    Hinojosa, C.7    Vargas-Vorackova, F.8    Sifuentes-Osornio, J.9
  • 110
    • 70349469854 scopus 로고    scopus 로고
    • Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: A double-blind, randomized, placebo-controlled multicenter trial
    • PMID:19590022
    • Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009; 180:640-8 PMID:19590022. http://dx.doi.org/10.1164/rccm.200903-0363OC
    • (2009) Am J Respir Crit Care Med , vol.180 , pp. 640-648
    • Meisel, C.1    Schefold, J.C.2    Pschowski, R.3    Baumann, T.4    Hetzger, K.5    Gregor, J.6    Weber-Carstens, S.7    Hasper, D.8    Keh, D.9    Zuckermann, H.10
  • 112
    • 0031962714 scopus 로고    scopus 로고
    • Effect of pentoxifylline in severe sepsis: Results of a randomized, double-blind, placebo-controlled study
    • PMID:9438767
    • Staubach KH, Schröder J, Stüber F, Gehrke K, Traumann E, Zabel P. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch Surg 1998; 133:94-100 PMID:9438767. http://dx.doi.org/10.1001/archsurg.133.1.94.
    • (1998) Arch Surg , vol.133 , pp. 94-100
    • Staubach, K.H.1    Schröder, J.2    Stüber, F.3    Gehrke, K.4    Traumann, E.5    Zabel, P.6
  • 113
    • 9144220131 scopus 로고    scopus 로고
    • Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)
    • Glaxo Wellcome International Septic Shock Study Group. PMID:14707554
    • Bakker J, Grover R, McLuckie A, Holzapfel L, Andersson J, Lodato R, Watson D, Grossman S, Donaldson J, Takala J; Glaxo Wellcome International Septic Shock Study Group. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002). Crit Care Med 2004; 32:1-12 PMID:14707554. http://dx.doi.org/10.1097/01.CCM.0000105118.66983.19.
    • (2004) Crit Care Med , vol.32 , pp. 1-12
    • Bakker, J.1    Grover, R.2    McLuckie, A.3    Holzapfel, L.4    Andersson, J.5    Lodato, R.6    Watson, D.7    Grossman, S.8    Donaldson, J.9    Takala, J.10
  • 114
    • 0025904893 scopus 로고
    • A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice
    • PMID:1826127
    • Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 1991; 173:1029-32 PMID:1826127. http://dx.doi.org/10.1084/jem.173.4.1029.
    • (1991) J Exp Med , vol.173 , pp. 1029-1032
    • Alexander, H.R.1    Doherty, G.M.2    Buresh, C.M.3    Venzon, D.J.4    Norton, J.A.5
  • 115
    • 0026772736 scopus 로고
    • Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia
    • PMID:1533231
    • Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, DeForge L, Kenney JS, Remick DG, Bloedow DC, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992; 89:1551-7 PMID:1533231. http://dx.doi.org/10.1172/JCI115748.
    • (1992) J Clin Invest , vol.89 , pp. 1551-1557
    • Fischer, E.1    Marano, M.A.2    van Zee, K.J.3    Rock, C.S.4    Hawes, A.S.5    Thompson, W.A.6    Deforge, L.7    Kenney, J.S.8    Remick, D.G.9    Bloedow, D.C.10
  • 116
    • 13344270905 scopus 로고    scopus 로고
    • Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081
    • PMID:8690912
    • Van Zee KJ, Moldawer LL, Oldenburg HS, Thompson WA, Stackpole SA, Montegut WJ, Rogy MA, Meschter C, Gallati H, Schiller CD, et al. Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J Immunol 1996; 156:2221-30 PMID:8690912.
    • (1996) J Immunol , vol.156 , pp. 2221-2230
    • van Zee, K.J.1    Moldawer, L.L.2    Oldenburg, H.S.3    Thompson, W.A.4    Stackpole, S.A.5    Montegut, W.J.6    Rogy, M.A.7    Meschter, C.8    Gallati, H.9    Schiller, C.D.10
  • 118
    • 0025008760 scopus 로고
    • Relationships between tumour necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice
    • PMID:2110016
    • Myers AK, Robey JW, Price RM. Relationships between tumour necrosis factor, eicosanoids and platelet-activating factor as mediators of endotoxin-induced shock in mice. Br J Pharmacol 1990; 99:499-502 PMID:2110016 http://dx.doi.org/10.1111/j.1476-5381.1990.tb12957.x
    • (1990) Br J Pharmacol , vol.99 , pp. 499-502
    • Myers, A.K.1    Robey, J.W.2    Price, R.M.3
  • 119
    • 0030036625 scopus 로고    scopus 로고
    • Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock
    • PMID:8818347
    • Giral M, Balsa D, Ferrando R, Merlos M, Garcia-Rafanell J, Forn J. Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock. Br J Pharmacol 1996; 118:1223-31 PMID:8818347. http://dx.doi.org/10.1111/j.1476-5381.1996.tb15527.x
    • (1996) Br J Pharmacol , vol.118 , pp. 1223-1231
    • Giral, M.1    Balsa, D.2    Ferrando, R.3    Merlos, M.4    Garcia-Rafanell, J.5    Forn, J.6
  • 120
    • 0027511114 scopus 로고
    • An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan
    • PMID:8423096
    • Ogata M, Matsumoto T, Koga K, Takenaka I, Kamochi M, Sata T, Yoshida S, Shigematsu A. An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan. Infect Immun 1993; 61:699-704 PMID:8423096.
    • (1993) Infect Immun , vol.61 , pp. 699-704
    • Ogata, M.1    Matsumoto, T.2    Koga, K.3    Takenaka, I.4    Kamochi, M.5    Sata, T.6    Yoshida, S.7    Shigematsu, A.8
  • 121
    • 70350304545 scopus 로고    scopus 로고
    • Analysis of binding site for the novel smallmolecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model
    • PMID:19563534
    • Takashima K, Matsunaga N, Yoshimatsu M, Hazeki K, Kaisho T, Uekata M, Hazeki O, Akira S, Iizawa Y, Ii M. Analysis of binding site for the novel smallmolecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br J Pharmacol 2009; 157:1250-62 PMID:19563534 http://dx.doi.org/10.1111/j.1476-5381.2009.00297.x
    • (2009) Br J Pharmacol , vol.157 , pp. 1250-1262
    • Takashima, K.1    Matsunaga, N.2    Yoshimatsu, M.3    Hazeki, K.4    Kaisho, T.5    Uekata, M.6    Hazeki, O.7    Akira, S.8    Iizawa, Y.9    Ii, M.10
  • 122
    • 34548496023 scopus 로고    scopus 로고
    • Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model
    • PMID:17632100
    • Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, Iizawa Y. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol 2007; 571:231-9 PMID:17632100. http://dx.doi.org/10.1016/j.ejphar.2007.06.027.
    • (2007) Eur J Pharmacol , vol.571 , pp. 231-239
    • Sha, T.1    Sunamoto, M.2    Kitazaki, T.3    Sato, J.4    Ii, M.5    Iizawa, Y.6
  • 123
    • 0027319678 scopus 로고
    • Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
    • PMID:8514893
    • Creasey AA, Chang AC, Feigen L, Wün TC, Taylor FB Jr., Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91:2850-60 PMID:8514893. http://dx.doi.org/10.1172/JCI116529
    • (1993) J Clin Invest , vol.91 , pp. 2850-2860
    • Creasey, A.A.1    Chang, A.C.2    Feigen, L.3    Wün, T.C.4    Taylor Jr., F.B.5    Hinshaw, L.B.6

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.